D Orazio & Associates Inc. Makes New Investment in Haleon plc (NYSE:HLN)

D Orazio & Associates Inc. bought a new position in Haleon plc (NYSE:HLN) in the fourth quarter, Holdings Channel reports. The firm bought 11,971 shares of the company’s stock, valued at approximately $114,000.

A number of other large investors have also bought and sold shares of HLN. Fortitude Family Office LLC purchased a new stake in Haleon in the third quarter worth $28,000. Versant Capital Management Inc increased its position in Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock worth $34,000 after buying an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in Haleon in the fourth quarter worth $35,000. Toronto Dominion Bank increased its position in Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after buying an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management purchased a new stake in Haleon in the fourth quarter worth $39,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Price Performance

Haleon stock opened at $9.55 on Friday. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80. The business has a 50-day simple moving average of $9.53 and a 200 day simple moving average of $9.78. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock has a market cap of $43.21 billion, a price-to-earnings ratio of 28.07, a PEG ratio of 2.70 and a beta of 0.28.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on HLN shares. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.